Cansino Biologics’ shares surged on mRNA deal with AstraZeneca

>>REAL-TIME UPDATES IN THE WIRE. CLICK HERE<<<

CanSino Biologics surged 15.5% in Hong Kong after it reached agreement with AstraZeneca to provide “contract development and manufacturing services” to support the drugmaker’s messenger RNA vaccine programme.

In a filing to Shanghai’s stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. It did not disclose the value of the deal.

AstraZeneca said the deal would support investigational mRNA vaccines in its early pipeline. “AstraZeneca is working on next-generation technologies to develop vaccines and monoclonal antibodies for infectious diseases where there is high unmet need,” the company said, adding it would share more details as the candidates progress.